Irinotecan Dose Adjustment Based on Genetic Testing in Colorectal Cancer
Author Information
Author(s): Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M
Primary Institution: Universitat Autònoma de Barcelona
Hypothesis
Irinotecan dose individualisation based on UGT1A1 genotype will improve treatment tolerance and efficacy in advanced colorectal cancer.
Conclusion
The study found that the maximum tolerated dose of irinotecan is significantly higher for patients with certain UGT1A1 genotypes compared to the standard dose.
Supporting Evidence
- The maximum tolerated dose of irinotecan was found to be higher for patients with UGT1A1 *1/*1 and *1/*28 genotypes.
- Patients with the *28/*28 genotype had a maximum tolerated dose that was 30% lower than the standard dose.
- Neutropenia and diarrhoea were the most common severe toxicities observed.
Takeaway
Doctors can give higher doses of a cancer drug called irinotecan to some patients based on their genes, which helps them tolerate the treatment better.
Methodology
Patients were treated with FOLFIRI and classified by UGT1A1 genotype to determine the maximum tolerated dose of irinotecan.
Limitations
The study did not include a pharmacokinetics analysis to describe the effect of different irinotecan doses on drug exposure.
Participant Demographics
{"median_age":63,"sex_distribution":{"male":61,"female":39},"ethnicity":"white"}
Statistical Information
P-Value
p<0.05
Confidence Interval
95%: 1.76–18.51
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website